Updated Clinical Pharmacokinetics and Pharmacodynamics of Oxycodone
Open Access
- 17 January 2019
- journal article
- review article
- Published by Springer Nature in Clinical Pharmacokinetics
- Vol. 58 (6) , 705-725
Abstract
Global oxycodone consumption has increased sharply during the last two decades, and, in 2008, oxycodone consumption surpassed that of morphine. As oxycodone was synthesized in 1916 and taken to clinical use a year later, it has not undergone the same approval process required by today’s standards. Most of the basic oxycodone pharmacokinetic (PK) data are from the 1990s and from academic research; however, a lot of additional data have been published over the last 10 years. In this review, we describe the latest oxycodone data on special populations, including neonates, children, pregnant and lactating women, and the elderly. A lot of important drug interaction data have been published that must also be taken into account when oxycodone is used concomitantly with cytochrome P450 (CYP) 3A inducers and inhibitors and/or CYP2D6 inhibitors. In addition, we gathered data on abuse-deterrent oxycodone formulations, and the PK of alternate administration routes, i.e. transmucosal and epidural, are also described.Keywords
Funding Information
- Kuopion Yliopistollinen Sairaala
- Olvi S??ti?, Iisalmi, Finland
- The Finnish Cultural Foundation, Helsinki, Finland
This publication has 161 references indexed in Scilit:
- Pharmacokinetics, Tolerability, and Safety of Intranasal Administration of Reformulated OxyContin® Tablets Compared with Original OxyContin® Tablets in Healthy AdultsClinical Drug Investigation, 2013
- CYP2D6 Genotype Dependent Oxycodone Metabolism in Postoperative PatientsPLOS ONE, 2013
- Functional expression of a proton-coupled organic cation (H+/OC) antiporter in human brain capillary endothelial cell line hCMEC/D3, a human blood–brain barrier modelFluids and Barriers of the CNS, 2013
- Do CYP2D6 genotypes reflect oxycodone requirements for cancer patients treated for cancer pain? A cross-sectional multicentre studyEuropean Journal of Clinical Pharmacology, 2011
- Miconazole Oral Gel Increases Exposure to Oral Oxycodone by Inhibition of CYP2D6 and CYP3A4Antimicrobial Agents and Chemotherapy, 2011
- Influences on the pharmacokinetics of oxycodone: a multicentre cross-sectional study in 439 adult cancer patientsEuropean Journal of Clinical Pharmacology, 2010
- Exposure to oral oxycodone is increased by concomitant inhibition of CYP2D6 and 3A4 pathways, but not by inhibition of CYP2D6 aloneBritish Journal of Clinical Pharmacology, 2010
- Genetic polymorphisms and drug interactions modulating CYP2D6 and CYP3A activities have a major effect on oxycodone analgesic efficacy and safetyBritish Journal of Pharmacology, 2010
- The effects of CYP2D6 and CYP3A activities on the pharmacokinetics of immediate release oxycodoneBritish Journal of Pharmacology, 2010
- Oxycodone induces overexpression of P‐glycoprotein (ABCB1) and affects paclitaxel's tissue distribution in Sprague Dawley ratsJournal of Pharmaceutical Sciences, 2007